Back to top
more

Zoetis (ZTS)

(Real Time Quote from BATS)

$171.66 USD

171.66
1,505,840

-4.19 (-2.38%)

Updated Jun 13, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).

Roche (RHHBY) Inks Deal to Acquire GenMark Diagnostics for $1.8B

by Zacks Equity Research

Roche (RHHBY) signs an agreement to acquire GenMark Diagnostics to test a broad range of pathogens using one patient sample. The deal is valued at around $1.8 billion on a fully diluted basis.

The Zacks Analyst Blog Highlights: Tapestry, Ulta Beauty, Synchrony Financial, CDW Corp and Zoetis

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Tapestry, Ulta Beauty, Synchrony Financial, CDW Corp and Zoetis

Sweta Killa headshot

5 Top-Ranked Stocks Backed by Women Power

by Sweta Killa

We have highlighted some top-ranked stocks from the S&P 500 that are headed by female CEOs and have massive upside potential in the coming years.

ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss

by Zacks Equity Research

ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.

USNA or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

USNA vs. ZTS: Which Stock Is the Better Value Option?

Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) beats both earnings and sales estimates in the fourth quarter of 2020.

Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?

by Zacks Equity Research

Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) will report earnings and revenues, and provide other pipeline updates when it releases fourth-quarter 2020 results.

Earnings Preview: Zoetis (ZTS) Q4 Earnings Expected to Decline

by Zacks Equity Research

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GRFS vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Zoetis (ZTS) Down 7.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zoetis (ZTS) Librela Gets Marketing Authorization in Europe

by Zacks Equity Research

Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.

Radius' (RDUS) Q3 Loss Matches Estimates, Revenues Miss

by Zacks Equity Research

Radius (RDUS) reports an in-line loss but misses sales estimates in the third quarter.

Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) beats earnings and sales estimates in the third quarter. The company raises 2020 guidance.

Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Prothena (PRTA) misses earnings and sales estimates in the third quarter of 2020.

Zoetis (ZTS) in Focus: Stock Moves 6.9% Higher

by Zacks Equity Research

Zoetis (ZTS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zoetis (ZTS) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of 23.60% and 10.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Zoetis (ZTS)

by Zacks Equity Research

Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Kinjel Shah headshot

Big Drug/Biotech Stock Q3 Earnings on Nov 5: REGN, BMY & More

by Kinjel Shah

Let us take a look at four big drug/biotech companies, REGN, BMY, INCY & ZTS, which are gearing up for their earnings release.

Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) Dental product volumes are expected to have declined significantly in the third quarter due to the extremely elective nature of the products.

Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) will provide updates on earnings, revenues and other pipeline developments when its releases third-quarter 2020 results.

Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.

Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.